.12.5 ,ug/ml) Pseudomonas aeruginosa strains, against which it proved generally fourfold more active than imipenem and meropenem. BO-2727's antipseudomonal activity and its broad spectrum merit further investigation for clinical use by itself, since it was stable in the presence of renal dehydropeptidase I.
Among a variety of 3-lactam antibiotics, imipenem was the first carbapenem antibiotic with a broad spectrum including Enterococcus faecalis and Pseudomonas aeruginosa (3, 4, 6) . Imipenem is, however, not used alone clinically because of its instability in the presence of dehydropeptidase I (DHP-I). Carbapenem antibiotics such as panipenem (RS-533), meropenem (SM-7338), and biapenem (LJC10,627) have been developed since the introduction of imipenem (8, 9, 13, 14) . Meropenem and biapenem, both of which have a ,3-methyl group at the 1 position of the nucleus, were reported to overcome instability in the presence of DHP-I without the help of a DHP-I inhibitor (5, 12) and to have increased potency against gram-negative bacteria, including P. aeruginosa. However, the emergence of carbapenemresistant P. aeruginosa has continued to be a concern (7, 10) . In the course of modification of carbapenem 2-side chains, we synthesized a new parenteral 1B-methyl carbapenem, BO-2727 (1R,5R,6S)-6-[(R)-1-hydroxyethyl]-2-{(35,55)-5-[(R) -1-hydroxy -3 -N-methylaminopropyl]pyrrolidin -3 -ylthio}-1-methyl-1-carbapen-2-em-3-carboxylic acid hydrochloride hydrate (Fig. 1) . The introduction of the methyl group at the 13 position and the pyrrolidinylthio side chain carrying a 1-hydroxy-3-N-methylamino-propyl group into the 2 position improved both stability in the presence of DHP-I and activity against Staphylococcus aureus and P. aeruginosa. In this report, we describe the in vitro antibacterial activities of BO-2727 against clinical isolates and its stability in the presence of DHP-I, and we compare the results with those obtained with reference antibiotics.
BO-2727 and meropenem were synthesized at the Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Tsukuba, Japan. Imipenem and amikacin were products of Banyu Pharmaceutical Co., Ltd., Tokyo, Japan. Ceftazidime was purchased from Nippon Glaxo Co., Ltd., Tokyo, Japan. The antibiotics were dissolved in a 50 mM 3-(Nmorpholino)propanesulfonic acid (MOPS) buffer (pH 7.0) on the day of use.
The clinical isolates used in this study were our stock cultures which have been collected since 1983 in Japan. Susceptibility testing was performed by a standard agar dilution technique with Mueller-Hinton agar (Difco Laboratories, Detroit, Mich.) based on the standards of the Japan Society of Chemotherapy (2) . The medium was supple-* Corresponding author. mented with 5% horse blood for streptococci, and chocolate agar was used for Haemophilus influenzae. For Bacteroides fragilis, GAM agar (Nissui Seiyaku Co., Ltd., Tokyo, Japan) was used. The culture grown overnight at 37°C was diluted to 106 CFU/ml, and about 2 x 103 CFU of the culture per spot was inoculated onto agar plates containing serial twofold dilutions of antibiotics with a replicating device (Microplanter; Sakuma Seisakusyo, Tokyo, Japan). The plates were incubated at 37°C for 20 h, except for methicillinresistant S. aureus and B. fragilis, which were incubated at 35°C for 20 h in Mueller-Hinton agar supplemented with 4% sodium chloride and at 37°C for 24 h in GasPak jars (BBL Microbiology Systems, Cockeysville, Md.), respectively. The MIC was defined as the lowest concentration of antibiotic which prevented visible growth.
The susceptibility of BO-2727 to hydrolysis by renal DHP-I was compared with those of imipenem and meropenem by using partially purified swine renal DHP-I (specific activity, 0.3 U/mg of protein). One unit of activity was defined as the amount of enzyme hydrolyzing 1 ,umol of glycyldehydrophenylalanine per min when the substrate (50 ,uM) was incubated at 35°C in 50 mM MOPS buffer, pH 7.0. The reaction mixture consisted of 50 ,uM substrate and 0.04 U of DHP-I per ml in 50 mM MOPS buffer (pH 7.0). Hydrolysis was monitored spectrophotometrically at 298, 299, and 298 nm for BO-2727, imipenem, and meropenem, respectively. The relative hydrolysis rate was determined, taking the hydrolysis rate of imipenem as 1.0.
The in vitro antibacterial activity of BO-2727 against the clinical isolates of 21 species was compared with those of meropenem, imipenem, and ceftazidime ( Streptococcus pyogenes (13) Streptococcus pneumoniae (13) Enterococcus faecalis (25) Escherichia coli (13) Kiebsiella pneumoniae (14)
Serratia marcescens (33)
Enterobacter cloacae (12) Citrobacterffreundii (13) Proteus mirabilis (13) tococcus pneumoniae, and E. faecalis at concentrations of 3.13 pg/ml or less. Imipenem was, however, fourfold more active than BO-2727 against methicillin-susceptible S. aureus and S. epidennidis. BO-2727 was also active against Escherichia coli, Klebsiella pneumoniae, Proteus spp., Providencia rettgeri, Morganella morganii, Citrobacterffreundii, Enterobacter cloacae, Serratia marcescens, H. influenzae, Branhamella catarrhalis, Acinetobacter calcoaceticus, and B. fragilis, with MICs for 90% of the strains tested ranging from 0.025 to 1.56 ,ug/ml. BO-2727 was 4-fold more active than imipenem against E. coli, E. cloacae, C. freundii, and Proteus mirabilis, but it was 4-fold to 16-fold less active 12.5 ,ug/ml) and those resistant to meropenem (MIC . 12.5 ,ug/ml). Of the 10 meropenem-resistant P. aeruginosa isolates, 2 were paradoxically susceptible to imipenem (MIC c 3.13 ,ug/ml), and 9 were inhibited by BO-2727 at 6.25 ,ug/ml or less.
T}he various strains producing well-characterized plasmidor chromosome-mediated 1-lactamases, except for P. cepacia and Xanthomonas maltophilia, were inhibited by BO-2727 at concentrations of .0.39 ,ug/ml ( Table 2 ). The strain of X. maltophilia that we tested is known to produce a carbapenem-hydrolyzing metalloenzyme (11) , by which all the carbapenems were hydrolyzed. The comparative study of the hydrolysis of the carbapenems by DHP-I showed that BO-2727 was quite stable in the presence of swine renal DHP-I showed that BO-2727 was quite stable in the presence of swine renal DHP-I. The relative hydrolysis rates were 0.11, 0.18 and 1.0 for BO-2727, meropenem, and imipenem, respectively.
In conclusion, BO-2727 is active against gram-positive and gram-negative bacteria, especially P. aeruginosa (including some imipenem-and/or meropenem-resistant strains) and is more stable in the presence of DHP-I than meropenem.
Therefore, BO-2727 merits further investigation for clinical use by itself.
